Update shared on23 Aug 2025
Fair value Increased 389%Zepp Health's consensus price target has surged, primarily reflecting sharply higher expected revenue growth and a much richer projected valuation multiple, now placing fair value at $60.23.
What's in the News
- Zepp Health issued Q3 2025 revenue guidance of $72–76 million, projecting a 23–35% year-over-year increase from $42.5 million.
- Amazfit launched Balance 2 smartwatch and Helio Strap, a screen-free fitness and recovery tracker, offering advanced performance tracking and integration within the Zepp App; Balance 2 retails for $299.99, Helio Strap for $99.99, and the bundle for $379.99.
- Amazfit introduced the Active 2 Square smartwatch, featuring a square sapphire glass AMOLED display, BioTracker 6.0 biosensor, up to 10-day battery life, enhanced heart rate/sleep algorithms, 160+ sports modes, offline maps, and Zepp Coach integration.
Valuation Changes
Summary of Valuation Changes for Zepp Health
- The Consensus Analyst Price Target has significantly risen from $12.32 to $60.23.
- The Future P/E for Zepp Health has significantly risen from 7.94x to 32.43x.
- The Consensus Revenue Growth forecasts for Zepp Health has significantly risen from 12.5% per annum to 21.9% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.